Chen Suli, Lin Yanjun, Gao Shuncai, Liu Shuo, Yang Zhanmin, Ma Ruiqing, Lu Liangyuan
Department of Anesthesiology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
Department of Myxomatology, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, China.
Front Oncol. 2024 Nov 27;14:1449171. doi: 10.3389/fonc.2024.1449171. eCollection 2024.
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a leading treatment for advanced ovarian cancer, significantly improving overall survival and disease-free survival. This case involves a patient with peritoneal metastasis and ultra-high intra-abdominal pressure (36 mmHg). CRS + HIPEC induces extensive pathological and physiological changes affecting respiratory, circulatory, renal, coagulation, and metabolic systems. Effective perioperative anesthesia management, including the type and volume of fluids administered, is crucial for optimizing patient outcomes. The complexities of anesthesia management in such cases present significant challenges.
细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)是晚期卵巢癌的主要治疗方法,可显著提高总生存率和无病生存率。本病例涉及一名伴有腹膜转移和超高腹腔内压力(36 mmHg)的患者。CRS+HIPEC会引发广泛的病理和生理变化,影响呼吸、循环、肾脏、凝血和代谢系统。有效的围手术期麻醉管理,包括所输注液体的类型和量,对于优化患者预后至关重要。此类病例的麻醉管理复杂性带来了重大挑战。